Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 23, 2026Clinical and Experimental MedicineOpen Access

CK2 in triple-negative breast cancer: oncogenic signaling networks and emerging CK2 inhibitor-based combination therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

NENavas Shereef EllyanAAAngel Treasa AlexUNUsha Y. Nayak

Discussion

Loading...

Member takes

Overview

Randomized trial investigates CK2's signaling impact in TNBC, suggesting improved treatment efficacy with CK2 inhibitors.

Key Points

  • The study aims to explore the role of CK2 in TNBC progression and the potential of CK2 inhibitors in enhancing treatment outcomes.
  • Examined the role of CK2 signaling in TNBC development and treatment resistance.
  • Investigated the effects of CK2 inhibition alone and in combination with various treatments in preclinical and clinical settings.
  • Analyzed the interactions between CK2 activity and oncogenic signaling pathways.
  • CK2 overactivation was associated with increased tumor growth and treatment resistance.
  • CK2 inhibitors showed significant synergistic effects with chemotherapy and targeted treatments.
  • Next-generation CK2 inhibitors demonstrated potential as effective therapeutic options in preclinical models.

Cite This Study

Ellyan et al. (2026) studied this question.

synapsesocial.com/papers/6a61aea0faa9903c51169d6ahttps://doi.org/10.1007/s10238-026-02256-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CK2 targeting potentiates antineoplastic effects of dual HER2/EGFR inhibitor lapatinib and attenuates growth factor-induced epithelial-mesenchymal transition2026
  2. 2An Integrative Computational Pipeline for CK2 Inhibitor Discovery in Triple−Negative Breast Cancer Using Virtual Screening, Molecular Dynamics, Machine Learning, and Density Functional Theory2026 · 1 citations
  3. 3Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer2024 · 2 citations
  4. 4Dynamic Phosphoproteomic Profiling Identifies Casein Kinase 2 as a Critical Survival Kinase in Quiescent Breast Cancer Cells and a Potential Therapeutic Target for Minimal Residual Disease2026
  5. 5Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions2024 · 92 citations